[
  {
    "ts": null,
    "headline": "Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts",
    "summary": "VIENNA (Reuters) -Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reuters, an early sign of the drugmaker's push to cut costs and regain ground on rival Eli Lilly.  The team, known internally as cardiometabolic educators, sat within Novo Nordisk's commercial division and included several hundred staff, sources said.",
    "url": "https://finnhub.io/api/news?id=5e08b82565b0a1bb6623261e788267c0034a2bf1b044a253ef0b24cf6f887a7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758227110,
      "headline": "Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts",
      "id": 136801776,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VIENNA (Reuters) -Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reuters, an early sign of the drugmaker's push to cut costs and regain ground on rival Eli Lilly.  The team, known internally as cardiometabolic educators, sat within Novo Nordisk's commercial division and included several hundred staff, sources said.",
      "url": "https://finnhub.io/api/news?id=5e08b82565b0a1bb6623261e788267c0034a2bf1b044a253ef0b24cf6f887a7a"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Surges as Ozempic Beats Lilly's Trulicity",
    "summary": "Real-world study shows fewer heart attacks, strokes, and deaths",
    "url": "https://finnhub.io/api/news?id=d5b9ab4da81f60b50e66714fcaea4198c744909f4ef630b89130c1f163f8f8a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758223999,
      "headline": "Novo Nordisk Surges as Ozempic Beats Lilly's Trulicity",
      "id": 136801777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Real-world study shows fewer heart attacks, strokes, and deaths",
      "url": "https://finnhub.io/api/news?id=d5b9ab4da81f60b50e66714fcaea4198c744909f4ef630b89130c1f163f8f8a7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents",
    "summary": "Eli Lilly and Co. (NYSE:LLY) is one of the best beginner stocks to buy, according to analysts. On September 17, the company announced that its diabetes medication, Mounjaro, delivered positive results in Phase 3 Trials in children and adolescents with type 2 diabetes. The diabetes medication reportedly demonstrated significant improvements in blood sugar control and […]",
    "url": "https://finnhub.io/api/news?id=65c3bac828020f707e8aa61604dbfd15d422604910408a0310a3ae1809d6c5a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758217205,
      "headline": "Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents",
      "id": 136801178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co. (NYSE:LLY) is one of the best beginner stocks to buy, according to analysts. On September 17, the company announced that its diabetes medication, Mounjaro, delivered positive results in Phase 3 Trials in children and adolescents with type 2 diabetes. The diabetes medication reportedly demonstrated significant improvements in blood sugar control and […]",
      "url": "https://finnhub.io/api/news?id=65c3bac828020f707e8aa61604dbfd15d422604910408a0310a3ae1809d6c5a3"
    }
  },
  {
    "ts": null,
    "headline": "Berenberg Upgrades Novo Nordisk (NVO) Amid Renewed Growth Outlook",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the best beginner stocks to buy, according to analysts. On September 17, Berenberg upgraded Novo Nordisk from ‘Hold’ to ‘Buy’, and revised its price target to DKK425.00, signaling a potential 20% upside. The move comes after a series of guidance downgrades that followed the company’s mid-2024 share price […]",
    "url": "https://finnhub.io/api/news?id=fb6ccc18a3127ecfba4e332a4fe9ceaa9947e73aeb0ff6088a6d30b2941f8059",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758217202,
      "headline": "Berenberg Upgrades Novo Nordisk (NVO) Amid Renewed Growth Outlook",
      "id": 136801179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the best beginner stocks to buy, according to analysts. On September 17, Berenberg upgraded Novo Nordisk from ‘Hold’ to ‘Buy’, and revised its price target to DKK425.00, signaling a potential 20% upside. The move comes after a series of guidance downgrades that followed the company’s mid-2024 share price […]",
      "url": "https://finnhub.io/api/news?id=fb6ccc18a3127ecfba4e332a4fe9ceaa9947e73aeb0ff6088a6d30b2941f8059"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "HEALTH NEWS  The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0737 GMT – Roche’s acquisition of 89bio adds a potential blockbuster to its drug pipeline, Vontobel’s Stefan Schneider writes.",
    "url": "https://finnhub.io/api/news?id=a1531e672eb3cbb12f6dd2a48146b9854246edfd090e2fdd147080abb2f56c1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758197100,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136798582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HEALTH NEWS  The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0737 GMT – Roche’s acquisition of 89bio adds a potential blockbuster to its drug pipeline, Vontobel’s Stefan Schneider writes.",
      "url": "https://finnhub.io/api/news?id=a1531e672eb3cbb12f6dd2a48146b9854246edfd090e2fdd147080abb2f56c1d"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today",
    "summary": "Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.",
    "url": "https://finnhub.io/api/news?id=5108feb914358c91ac72054c42ee9f964a29a0fa93e8012e9903c027f08b16f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758215100,
      "headline": "Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today",
      "id": 136801181,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.",
      "url": "https://finnhub.io/api/news?id=5108feb914358c91ac72054c42ee9f964a29a0fa93e8012e9903c027f08b16f9"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Pops On 'Significant' Weight Loss For Oral Wegovy",
    "summary": "Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a \"significant\" amount of weight.",
    "url": "https://finnhub.io/api/news?id=65e23f64346fe2cce2caa94d83c0c7d13c48fb0d7a642198725f2ceed5144e96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758214428,
      "headline": "Novo Nordisk Pops On 'Significant' Weight Loss For Oral Wegovy",
      "id": 136799507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a \"significant\" amount of weight.",
      "url": "https://finnhub.io/api/news?id=65e23f64346fe2cce2caa94d83c0c7d13c48fb0d7a642198725f2ceed5144e96"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs",
    "summary": "The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question. On Sept. 9, the agency sent warning letters to Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Hims & Hers Health, Inc (NYSE:HIMS) for what it perceives to be exaggerating the advantages of their GLP-1 weight-loss medications and underestimating severe threats. Check out the current price of HIMS stock here. The",
    "url": "https://finnhub.io/api/news?id=aa65e6d13b99708b4c52e79eb3dfb1d0c22a01c45a1ee5e38e6f687a0977ac4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758214264,
      "headline": "Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs",
      "id": 136799508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question. On Sept. 9, the agency sent warning letters to Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Hims & Hers Health, Inc (NYSE:HIMS) for what it perceives to be exaggerating the advantages of their GLP-1 weight-loss medications and underestimating severe threats. Check out the current price of HIMS stock here. The",
      "url": "https://finnhub.io/api/news?id=aa65e6d13b99708b4c52e79eb3dfb1d0c22a01c45a1ee5e38e6f687a0977ac4c"
    }
  },
  {
    "ts": null,
    "headline": "LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?",
    "summary": "Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.",
    "url": "https://finnhub.io/api/news?id=bd5665e2121d65198f25c6c4f00aa68f0c80f7b71cc4194f1cf25622d7457235",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758212400,
      "headline": "LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?",
      "id": 136801182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.",
      "url": "https://finnhub.io/api/news?id=bd5665e2121d65198f25c6c4f00aa68f0c80f7b71cc4194f1cf25622d7457235"
    }
  },
  {
    "ts": null,
    "headline": "eCIO Initiates Stake in Eli Lilly and Company (LLY) with 886 Shares",
    "summary": "Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During the first quarter, eCIO Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) through the purchase of 886 shares. According to the latest disclosure with the SEC, the firm’s […]",
    "url": "https://finnhub.io/api/news?id=5e7398c211f5132634513e3105a9ae825660b052407318d75cd71d57428481a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758211052,
      "headline": "eCIO Initiates Stake in Eli Lilly and Company (LLY) with 886 Shares",
      "id": 136799509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During the first quarter, eCIO Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) through the purchase of 886 shares. According to the latest disclosure with the SEC, the firm’s […]",
      "url": "https://finnhub.io/api/news?id=5e7398c211f5132634513e3105a9ae825660b052407318d75cd71d57428481a7"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Jumps. What the Latest New Ozempic Data Shows.",
    "summary": "In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.",
    "url": "https://finnhub.io/api/news?id=bfa7fb75fa7991fbbc1ae80b597e2d017e04d7dbe649a0e77842ce70b504cdec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758210900,
      "headline": "Novo Nordisk Stock Jumps. What the Latest New Ozempic Data Shows.",
      "id": 136799510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.",
      "url": "https://finnhub.io/api/news?id=bfa7fb75fa7991fbbc1ae80b597e2d017e04d7dbe649a0e77842ce70b504cdec"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Jump as Ozempic Outperforms Lilly's Trulicity in Heart Study",
    "summary": "Shares rise 6% premarket on new data in diabetic patients",
    "url": "https://finnhub.io/api/news?id=900670fdd034f4f0cf03d04b53c57af9f6f98ddf3d8c24ef6aea891b22cabaf9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758208906,
      "headline": "Novo Nordisk Shares Jump as Ozempic Outperforms Lilly's Trulicity in Heart Study",
      "id": 136800345,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares rise 6% premarket on new data in diabetic patients",
      "url": "https://finnhub.io/api/news?id=900670fdd034f4f0cf03d04b53c57af9f6f98ddf3d8c24ef6aea891b22cabaf9"
    }
  },
  {
    "ts": null,
    "headline": "The Promise and Hurdles of the New Weight-Loss Pills",
    "summary": "Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.",
    "url": "https://finnhub.io/api/news?id=8e771a92d7795d98bf71ec85f588f919d361aac4dd7c812a5f3f95642ded7a0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758207600,
      "headline": "The Promise and Hurdles of the New Weight-Loss Pills",
      "id": 136799511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.",
      "url": "https://finnhub.io/api/news?id=8e771a92d7795d98bf71ec85f588f919d361aac4dd7c812a5f3f95642ded7a0b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study",
    "summary": "Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s (NYSE:LLY) tirzepatide treatment in people with overweight or obesity and established CVD without diabetes. Data Compared with tirzepatide, Wegovy showed a signif",
    "url": "https://finnhub.io/api/news?id=d0735c7481ef985edd04bdddc98060aa73fa0e6a55ef7634b313310b69bb0040",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758203853,
      "headline": "Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study",
      "id": 136798590,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s (NYSE:LLY) tirzepatide treatment in people with overweight or obesity and established CVD without diabetes. Data Compared with tirzepatide, Wegovy showed a signif",
      "url": "https://finnhub.io/api/news?id=d0735c7481ef985edd04bdddc98060aa73fa0e6a55ef7634b313310b69bb0040"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.",
    "summary": "In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.",
    "url": "https://finnhub.io/api/news?id=3d31e64ea4f2c3ffc011c8f36736783783568edcbeca4a858942ed3aa29c907c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758201240,
      "headline": "Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.",
      "id": 136797576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.",
      "url": "https://finnhub.io/api/news?id=3d31e64ea4f2c3ffc011c8f36736783783568edcbeca4a858942ed3aa29c907c"
    }
  },
  {
    "ts": null,
    "headline": "GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors",
    "summary": "GAITHERSBURG, Md., September 18, 2025--GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors",
    "url": "https://finnhub.io/api/news?id=d7ebb08049005e2e5068c9a8893b19f635dc37a4225432c925249cb6515dfb48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758200400,
      "headline": "GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors",
      "id": 136797577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GAITHERSBURG, Md., September 18, 2025--GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors",
      "url": "https://finnhub.io/api/news?id=d7ebb08049005e2e5068c9a8893b19f635dc37a4225432c925249cb6515dfb48"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to build $5B cancer drug facility in Virginia",
    "summary": "It is expected to create 650 jobs and is one of four U.S. manufacturing facilities the pharmaceutical giant plans to unveil this year.",
    "url": "https://finnhub.io/api/news?id=3eb99b8eb0a92be15e62981c143a318afea6ac6c7f2f80dda1d7dfb589bdd7fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758198660,
      "headline": "Lilly to build $5B cancer drug facility in Virginia",
      "id": 136799513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It is expected to create 650 jobs and is one of four U.S. manufacturing facilities the pharmaceutical giant plans to unveil this year.",
      "url": "https://finnhub.io/api/news?id=3eb99b8eb0a92be15e62981c143a318afea6ac6c7f2f80dda1d7dfb589bdd7fc"
    }
  },
  {
    "ts": null,
    "headline": "Trump, Markets Got the Fed Rate Cut They Wanted. Why Both May Become Disappointed.",
    "summary": "Fed sees more downside risks for unemployment, Lilly and Novo Nordisk press ahead in weight-loss pill race, Walmart pushes to become a leader in agentic AI, and more news to start your day.",
    "url": "https://finnhub.io/api/news?id=ec9dc1c3a88ea2ed9b8a6d644c3c6a8d1234703fea49fbf88967e415d5e306e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758195900,
      "headline": "Trump, Markets Got the Fed Rate Cut They Wanted. Why Both May Become Disappointed.",
      "id": 136797478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Fed sees more downside risks for unemployment, Lilly and Novo Nordisk press ahead in weight-loss pill race, Walmart pushes to become a leader in agentic AI, and more news to start your day.",
      "url": "https://finnhub.io/api/news?id=ec9dc1c3a88ea2ed9b8a6d644c3c6a8d1234703fea49fbf88967e415d5e306e2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Upstages Novo Nordisk in Obesity Pill Face-Off",
    "summary": "Both companies have been desperate to innovate beyond their current injectable GLP-1 weight-loss drugs for a while now.",
    "url": "https://finnhub.io/api/news?id=4229692bc413270c93de76a2b6c8990b93a2af3fa72b940d093864030f3cb833",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758195000,
      "headline": "Eli Lilly Upstages Novo Nordisk in Obesity Pill Face-Off",
      "id": 136801183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Both companies have been desperate to innovate beyond their current injectable GLP-1 weight-loss drugs for a while now.",
      "url": "https://finnhub.io/api/news?id=4229692bc413270c93de76a2b6c8990b93a2af3fa72b940d093864030f3cb833"
    }
  },
  {
    "ts": null,
    "headline": "Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion",
    "summary": "The deal seeks to strengthen the drugmaker’s pipeline by adding an experimental treatment for a liver disease linked to obesity.",
    "url": "https://finnhub.io/api/news?id=4c480df162a9faaf9ce8ffd403b8968ca292a1e62b202ebef76a2f64c6a26cb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758193380,
      "headline": "Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion",
      "id": 136797579,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal seeks to strengthen the drugmaker’s pipeline by adding an experimental treatment for a liver disease linked to obesity.",
      "url": "https://finnhub.io/api/news?id=4c480df162a9faaf9ce8ffd403b8968ca292a1e62b202ebef76a2f64c6a26cb0"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Nvidia, Meta, Novo Nordisk, IonQ and Next",
    "summary": "The latest investor updates on stocks that are trending on Thursday.",
    "url": "https://finnhub.io/api/news?id=c8f2e5d78f2b2cf92a605bcb095d780a8ad931ca9600409eb867428a2c00ea85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758189414,
      "headline": "Trending tickers: Nvidia, Meta, Novo Nordisk, IonQ and Next",
      "id": 136797459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Thursday.",
      "url": "https://finnhub.io/api/news?id=c8f2e5d78f2b2cf92a605bcb095d780a8ad931ca9600409eb867428a2c00ea85"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Growth Stocks You Can Buy and Forget About",
    "summary": "These stocks have been raising their payouts for years and they're likely going to continue doing so for the foreseeable future.",
    "url": "https://finnhub.io/api/news?id=d25df16e7ac2b981d0d3a6016d9a395aee4f29b980bcce69e4cd7982cf5b8e74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758189000,
      "headline": "3 Dividend Growth Stocks You Can Buy and Forget About",
      "id": 136797440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These stocks have been raising their payouts for years and they're likely going to continue doing so for the foreseeable future.",
      "url": "https://finnhub.io/api/news?id=d25df16e7ac2b981d0d3a6016d9a395aee4f29b980bcce69e4cd7982cf5b8e74"
    }
  },
  {
    "ts": null,
    "headline": "It Is Time To Buy Novo Nordisk Hand Over Fist",
    "summary": "Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.",
    "url": "https://finnhub.io/api/news?id=f26d7f9d18be7c9d325c14942cd167cc0a9c060fce57599bb030fe95427afe83",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758188162,
      "headline": "It Is Time To Buy Novo Nordisk Hand Over Fist",
      "id": 136798863,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153927815/image_2153927815.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.",
      "url": "https://finnhub.io/api/news?id=f26d7f9d18be7c9d325c14942cd167cc0a9c060fce57599bb030fe95427afe83"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Says Mounjaro Meets Endpoints in Study of Children, Adolescents With Type 2 Diabetes",
    "summary": "Eli Lilly (LLY) said late Wednesday its Mounjaro drug met primary and secondary endpoints at week 30",
    "url": "https://finnhub.io/api/news?id=04d901f2a4833cace90fa6608846f5fa175f0f35a3684303daa8736a1da50263",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758186525,
      "headline": "Eli Lilly Says Mounjaro Meets Endpoints in Study of Children, Adolescents With Type 2 Diabetes",
      "id": 136797582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said late Wednesday its Mounjaro drug met primary and secondary endpoints at week 30",
      "url": "https://finnhub.io/api/news?id=04d901f2a4833cace90fa6608846f5fa175f0f35a3684303daa8736a1da50263"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
    "summary": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
    "url": "https://finnhub.io/api/news?id=5012163a0b9c923a901057751f776bbdcd3475f9ef269f62f80bfa7c4d326b32",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758184620,
      "headline": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
      "id": 136803524,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
      "url": "https://finnhub.io/api/news?id=5012163a0b9c923a901057751f776bbdcd3475f9ef269f62f80bfa7c4d326b32"
    }
  },
  {
    "ts": null,
    "headline": "The Fed Will Cut Rates Again, And Again",
    "summary": "The Fed's 25bps cut highlights growing labor market concerns, with more cuts expected in 2025 amid shifting opportunities. Find out why safe investing still matters.",
    "url": "https://finnhub.io/api/news?id=b05582c06572a719a90628e1d75adc7b931c916c97894d12a9b66aecfc55a7d3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758184200,
      "headline": "The Fed Will Cut Rates Again, And Again",
      "id": 136797384,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2226826422/image_2226826422.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Fed's 25bps cut highlights growing labor market concerns, with more cuts expected in 2025 amid shifting opportunities. Find out why safe investing still matters.",
      "url": "https://finnhub.io/api/news?id=b05582c06572a719a90628e1d75adc7b931c916c97894d12a9b66aecfc55a7d3"
    }
  }
]